ASXL1 and myelodysplastic syndrome: At disease presentation, 92.86% of MDS cases (13/14) had a coding mutation in at least one gene included in the six commonly mutated pathways: epigenetics (9/14, 64.29%), including DNA methylation-related genes DNMT3A, TET2, and IDH1 (7/14, 50%) and chromatin/histone modifiers EZH2 and ASXL1 (5/14, 35.71%); transcription factors (6/14, 42.86%); RNA splicing (6/14, 42.86%); signaling genes (4/14, 28.57%); TP53 (3/14, 21.43%) as example of DNA damage response, and STAG2 as example of the cohesin complex (2/14, 14.29%; Fig. 1B).